
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc is positioned favorably within the expanding market for respiratory infectious disease diagnostics, particularly in the Middle East, due to strategic investments in the region, notably from the Kingdom of Saudi Arabia. The company's partnership with Arabian Eagle Manufacturing to commercialize its Co-Dx technologies across 19 MENA nations demonstrates its commitment to enhancing access to affordable PCR testing, especially in areas with significant healthcare needs. Additionally, Co-Diagnostics is advancing its proprietary Co-Dx PCR platform through critical regulatory pathways, underscoring its potential for growth beyond tuberculosis and reinforcing a positive outlook for the company's future in the molecular diagnostics sector.
Bears say
Co-Diagnostics Inc. faces significant risks that contribute to a negative outlook on its stock, including the potential for failure in clinical evaluations and challenges in securing regulatory clearance for its instruments and tests in the U.S. The company reported a revenue of only $145,000 for the third quarter of 2025, alongside a substantial net loss of $5.9 million, equating to a loss of $0.16 per share. Additionally, there are concerns regarding the upcoming capital raise, which is expected to be more dilutive and possibly present less favorable terms than previous raises, further impacting shareholder value.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares